{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Upper+Tract+Urothelial+Carcinomas&page=2",
    "query": {
      "condition": "Upper Tract Urothelial Carcinomas",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Upper+Tract+Urothelial+Carcinomas&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:43:32.696Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05868265",
      "title": "A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Radical surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-06-02",
      "completion_date": "2027-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 8,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05868265"
    },
    {
      "nct_id": "NCT06040762",
      "title": "A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Upper Tract Urothelial Carcinoma",
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "App-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Wearable Activity Tracker",
          "type": "OTHER"
        },
        {
          "name": "Physical Performance Testing",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2023-12-19",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06040762"
    },
    {
      "nct_id": "NCT04006691",
      "title": "Efficacy and Safety of UGN-101 in Recurrent Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma",
        "Transitional Cell Carcinoma",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "UGN-101 instillations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-01",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-05-07",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006691"
    },
    {
      "nct_id": "NCT04197986",
      "title": "Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Upper Tract Urothelial Carcinomas",
        "Urothelial Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-03-11",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 47,
      "location_summary": "Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197986"
    },
    {
      "nct_id": "NCT02701023",
      "title": "Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Urothelial Carcinoma Ureteral Location"
      ],
      "interventions": [
        {
          "name": "MitoGel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "76 Years",
        "maximum_age": "77 Years",
        "sex": "MALE",
        "summary": "76 Years to 77 Years · Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02701023"
    },
    {
      "nct_id": "NCT01031420",
      "title": "Dose Dense MVAC for Muscle Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Invasive Bladder Cancer",
        "High Risk Urothelial Carcinoma of the Upper Urinary Tracts"
      ],
      "interventions": [
        {
          "name": "single arm dose dense MVAC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2009-12-07",
      "completion_date": "2013-08-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031420"
    },
    {
      "nct_id": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "feladilimab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-11-26",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693612"
    },
    {
      "nct_id": "NCT04228042",
      "title": "Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-07-28",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04228042"
    },
    {
      "nct_id": "NCT06310759",
      "title": "Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Tampere University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3000,
      "start_date": "2024-01-08",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06310759"
    },
    {
      "nct_id": "NCT07265947",
      "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Upper Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dabogratinib (TYRA-300) 60mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) 80mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-12-22",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T03:43:32.696Z",
      "location_count": 5,
      "location_summary": "Lisle, Illinois • Jeffersonville, Indiana • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Lisle",
          "state": "Illinois"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07265947"
    }
  ]
}